India is the first large market in the world with generic semaglutide. That one fact reorganised everything else — what is on the shelf, what it costs, and what a manufacturer will bother to launch here next.
This is a reference page, not a recommendation. It exists because the honest answer to "what does this cost in India" changed several times in 2026, and because most pages that answer it are selling something.
Nothing here is a prescription, a quote, or a reason to start. GLP-1 receptor agonists are Schedule H medicines in India: prescription-only, and prescription-only for reasons that have nothing to do with paperwork. Read the safety section before you read the prices.
On this page
- Where these molecules came from
- What it costs in India
- Insurance
- Indications — where India leads, matches and lags
- What is actually coming
- Safety, and why a prescriber is mandatory
Where these molecules came from
The chemistry is global and the timeline is genuinely a sequence — each drug's design solves the failure of the one before it. Native GLP-1 lasts one to two minutes in the body. Everything since 1992 is, in one form or another, an answer to that problem.
India enters this story late and then closes the gap in a rush.
1960s–70s
The incretin effect is named
Oral glucose triggers far more insulin than the same glucose given intravenously. The gut hormone responsible for the gap — GIP — is the first incretin identified.
Early 1980s
GLP-1 is isolated as the dominant incretin
The proglucagon gene is cloned. Biochemist Svetlana Mojsov identifies the truncated, active form of GLP-1 and shows it triggers insulin secretion at roughly a hundredth of the concentration GIP needs. Her role went under-credited for decades and remains a live authorship dispute.
1992
A Gila monster solves the half-life problem
Native GLP-1 is broken down by the enzyme DPP-4 within one to two minutes — physiologically interesting, pharmacologically useless. At the Bronx VA, John Eng isolates exendin-4 from the venom of Heloderma suspectum. It binds the GLP-1 receptor but resists DPP-4, surviving hours instead of minutes. The NIH declines to patent it; Eng does.
28 April 2005
Exenatide (Byetta) — first in class
A twice-daily injection, for type 2 diabetes only. It reaches India roughly two years later, in 2007.
2010
Liraglutide (Victoza)
The first once-daily human GLP-1 analogue. It launches in India the same year — the shortest global-to-India gap this class has ever had.
2014
Dulaglutide (Trulicity)
Once-weekly dosing becomes viable. It reaches India roughly 2017–18.
December 2014
Saxenda — the pivot to weight management
Higher-dose liraglutide becomes the first GLP-1 approved specifically for chronic weight management rather than diabetes. It never becomes a mass-market product in India.
5 December 2017
Semaglutide (Ozempic)
Once-weekly and substantially more potent than anything before it, for type 2 diabetes. India will not see it until 12 December 2025 — an eight-year gap, and barely three months before its own Indian patent expires.
September 2019
Oral semaglutide (Rybelsus)
The first oral GLP-1: a peptide paired with an absorption enhancer. India launch follows in 2022, roughly three years later.
4 June 2021
Wegovy — obesity, and the cultural inflection point
Semaglutide for obesity posts around 15% mean weight loss in STEP-1, an effect size previously reserved for bariatric surgery. Between 2021 and 2023 the class stops being a diabetes drug in the public mind. India launch: June 2025 — notably before Ozempic.
13 May 2022
Tirzepatide (Mounjaro) — the first dual agonist
The first drug to combine GIP and GLP-1 receptor agonism in one molecule, for type 2 diabetes. India launch March 2025 — a roughly three-year gap, its shortest for a major molecule since Victoza.
8 November 2023
Zepbound — tirzepatide for obesity
Around 22.5% weight loss at the top dose in SURMOUNT-1. Not sold under this brand in India; Mounjaro carries both the diabetes and the obesity label there.
September – December 2025
The WHO ratifies the reframing
GLP-1 therapies are added to the WHO Essential Medicines List for high-risk type 2 diabetes in September 2025, followed by formal WHO guidelines on GLP-1/GIP dual agonists for obesity on 1 December 2025. Obesity is now treated as a pharmacologically addressable chronic disease.
20 March 2026
India's semaglutide patent expires
Patent IN 262697 lapses and generics are on shelves within a day — Natco, Dr. Reddy's, Sun Pharma, Cipla, Glenmark, Alkem and Zydus in the first wave. India becomes the first large market in the world with generic semaglutide, roughly five years ahead of the United States.
1 April 2026
Orforglipron (Foundayo)
The first non-peptide, small-molecule oral GLP-1 — ordinary chemical synthesis, no fermentation capacity limit, no food or water timing restriction. That structural shift is what eventually breaks the manufacturing bottleneck behind this whole class.
The India lag, drug by drug
| Drug | Global approval | India entry | Lag |
|---|---|---|---|
| Exenatide (Byetta) | 2005 | 2007 | ~2 years |
| Liraglutide (Victoza) | 2010 | 2010 | None |
| Dulaglutide (Trulicity) | 2014 | ~2017–18 | ~3 years |
| Oral semaglutide (Rybelsus) | 2019 | 2022 | ~3 years |
| Tirzepatide (Mounjaro) | 2022 | March 2025 | ~3 years |
| Semaglutide for obesity (Wegovy) | 2021 | June 2025 | ~4 years |
| Semaglutide for diabetes (Ozempic) | 2017 | December 2025 | ~8 years |
Two things stand out. Ozempic arrived in India eight years after its global approval and barely three months before the Indian patent protecting it expired — a sequencing decision, not an accident. And Wegovy arrived before Ozempic, which tells you where the manufacturer thought the Indian money was.
What it costs in India
Every rupee figure on this page lives in one dataset and is rendered from it. The prose deliberately does not repeat any of them, so a correction is made once and is correct everywhere.
Every priced GLP-1 product on sale in India
India MRP, verified 11 May 2026. These prices have moved every few weeks since the patent expiry. Read them as the shape of the market, not as a quote — what a pharmacy charges you depends on the city, the retailer and the day.
| Indian indication | |||||
|---|---|---|---|---|---|
| Semanat | Natco Pharma | 2 mgVial | Weight management | ₹325 | ₹1,290 |
| GLIPIQ | Glenmark Pharma | 2 mgVial | Weight management | ₹325 | ₹1,300 |
| Semasize | Alkem Labs | 0.25 mgPen | Weight management | ₹450 | ₹1,800 |
| Obeda — see note 1 | Dr. Reddy's | 0.25 mgPen | Type 2 diabetes at launch | ₹1,050 | ₹4,200 |
| Ozempic — see note 2 | Novo Nordisk | 0.25 mgPen | Type 2 diabetes | ₹1,415 | ₹5,660 |
| Wegovy | Novo Nordisk | 0.25 mgPen | Obesity (CDSCO-approved); non-cirrhotic MASH with moderate-to-advanced fibrosis | ₹1,415 | ₹5,660 |
| Wegovy — see note 3 | Novo Nordisk | 1.7 mgPen | Obesity (CDSCO-approved) | ₹3,000 | ₹12,000 |
| Mounjaro — see note 4 | Eli Lilly | 2.5 mgKwikPen | Type 2 diabetes and obesity | ₹3,281 | ₹13,125 |
| Mounjaro | Eli Lilly | 5 mgKwikPen | Type 2 diabetes and obesity | approximately, computed from the monthly figure: ₹4,102 | ₹16,406 |
| Mounjaro | Eli Lilly | 7.5–10 mgKwikPen | Type 2 diabetes and obesity | approximately, computed from the monthly figure: ₹5,156 | ₹20,625 |
| Mounjaro — figure disputed across sources, see the re-verify panel — see note 5 | Eli Lilly | 12.5–15 mgKwikPen | Type 2 diabetes and obesity | approximately, computed from the monthly figure: ₹6,445 | ₹25,781 |
Semanat
Natco Pharma
- Strength
- 2 mg · Vial
- Indication
- Weight management
GLIPIQ
Glenmark Pharma
- Strength
- 2 mg · Vial
- Indication
- Weight management
Semasize
Alkem Labs
- Strength
- 0.25 mg · Pen
- Indication
- Weight management
Obeda — see note 1
Dr. Reddy's
- Strength
- 0.25 mg · Pen
- Indication
- Type 2 diabetes at launch
Ozempic — see note 2
Novo Nordisk
- Strength
- 0.25 mg · Pen
- Indication
- Type 2 diabetes
Wegovy
Novo Nordisk
- Strength
- 0.25 mg · Pen
- Indication
- Obesity (CDSCO-approved); non-cirrhotic MASH with moderate-to-advanced fibrosis
Wegovy — see note 3
Novo Nordisk
- Strength
- 1.7 mg · Pen
- Indication
- Obesity (CDSCO-approved)
Mounjaro — see note 4
Eli Lilly
- Strength
- 2.5 mg · KwikPen
- Indication
- Type 2 diabetes and obesity
Mounjaro
Eli Lilly
- Strength
- 5 mg · KwikPen
- Indication
- Type 2 diabetes and obesity
Mounjaro
Eli Lilly
- Strength
- 7.5–10 mg · KwikPen
- Indication
- Type 2 diabetes and obesity
Mounjaro — figure disputed across sources, see the re-verify panel — see note 5
Eli Lilly
- Strength
- 12.5–15 mg · KwikPen
- Indication
- Type 2 diabetes and obesity
Italic figures were computed from the monthly figure in the same row, not read from a source.
Sources disagree on this figure — see the re-verify panel.
Weight-management label expansion pending at time of writing; listed under its launch indication.
Reflects the 1 April 2026 Novo Nordisk price cut (24–48% across doses).
Patients titrate from the 0.25 mg starter to this maintenance strength over roughly 16 weeks.
Also supplied as a vial. Obstructive sleep apnea use in India is off-label.
The same source page later shows ₹13,000/month at 15 mg. Unreconciled — see the conflicts note.
On Indian shelves, no reliable price
Listed rather than dropped — leaving them out would make this market look injection-only, which it is not.
Rybelsus · Novo Nordisk
Semaglutide · Daily tablet
First oral GLP-1, India launch 2022. Reported monthly figures conflict across sources; no reliable per-strength price.
Semalix · Torrent Pharma
Semaglutide · Daily tablet
Generic oral semaglutide, on Indian shelves post-patent-expiry. No published per-strength price found.
Figures a doctor should re-verify before quoting4 open discrepancies in the sourcing behind this table.
Tirzepatide at the top of the ladder: ₹25,781/month (12.5–15 mg) versus ₹13,000/month (15 mg), both from the same source page at different times.
Wegovy's June 2025 launch price: ₹4,336.25 'per dose' versus a reported ₹17,345+/month — likely a per-dose-vs-per-pack framing difference, not reconciled.
Oral semaglutide (Rybelsus): a ₹5,660/month figure appears in one place, identical to the Ozempic starter figure, which reads as a transcription artefact rather than a real price.
All retail figures originate from commercial aggregators and clinic pages, cross-consistent with wire reporting but not independently verified rupee-by-rupee against a manufacturer price list.
How these numbers got here
- 24 June 2025 — Wegovy launches in India. Its reported launch price is one of the unreconciled figures in the re-verify panel above.
- August 2025 — the Mounjaro KwikPen launches. Its launch price is single-sourced and is not treated as verified here.
- 26 September 2025 — Ozempic receives CDSCO approval, clearing the way for an India launch.
- 9 December 2025 — the CDSCO Endocrinology and Metabolism Subject Expert Committee approves additional formulations and the MASH indication for Wegovy.
- 12 December 2025 — Ozempic launches in India.
- 20 March 2026 — semaglutide patent IN 262697 expires. Generics are on shelves within a day: Natco, Dr. Reddy's, Sun Pharma, Cipla, Glenmark, Alkem and Zydus in the first wave.
- 1 April 2026 — Novo Nordisk cuts Ozempic and Wegovy prices by 24–48% across doses.
- May 2026 — Mounjaro is reported to have become the top-selling drug in Indian pharma by monthly sales. The specific sales figure is single-sourced and is not treated as verified here.
The 2025 dates above come from a single commercial source and have not been cross-checked against a second one. They are included because the sequence is the point; treat each individual date as provisional.
What a first month actually costs
The medicine is one line item out of four. A quoted “starting price” that mentions only the injection is not the number you will pay.
Initial video consultation
₹1,499
30-minute doctor consultation under NMC Telemedicine Practice Guidelines 2020. Includes a prescription if baseline labs are already complete.
Baseline labs
₹1,500–2,500
HbA1c, fasting insulin, lipid panel, liver and kidney function, TSH, vitamin D and B12, at any NABL-accredited lab.
First-month medication
₹1,290–13,125
Generic semaglutide at the low end, originator semaglutide in the middle, tirzepatide at the high end of the starting tier.
Cold-chain delivery
Usually included
2–8°C temperature-controlled logistics, typically bundled by pharmacy partners above roughly ₹1,000 order value.
Total, first month — by path
- Generic semaglutide path
- ≈ ₹4,300–6,500
- Originator semaglutide path
- ≈ ₹8,700–9,500
- Tirzepatide path
- ≈ ₹16,000–17,000
Follow-up consultations and repeat labs at month three and month six are not in these totals, and dose escalation raises the medication line over time. Those are the two costs most often missing from a quoted starting price.
Insurance
No IRDAI-regulated policy covers the obesity indication. As of May 2026 that is unambiguous across every major insurer checked — Star Health, ICICI Lombard, HDFC ERGO, Niva Bupa and Care Health. Indian health policies were built as inpatient-hospitalisation products. An outpatient prescription injectable sits outside that architecture entirely, and weight-loss medication is frequently named as an explicit exclusion rather than simply going unmentioned.
The type 2 diabetes indication is a narrower, partial exception. Some diabetes-specific outpatient riders — Star Health's Diabetes Safe and Care Health's diabetes plans among them — reimburse insulin and oral antidiabetics from day one, and a small fraction extend to GLP-1 receptor agonists when prescribed for documented type 2 diabetes by an endocrinologist or diabetologist. The documentation typically expected is an HbA1c of 6.5% or above, or fasting glucose of 126 mg/dL or above. These are adjudicated case by case and should never be assumed in advance.
A handful of large corporate group plans reportedly reimburse Ozempic for type 2 diabetes under a chronic-disease-management rider, but no major Indian corporate plan covers obesity-alone prescribing. That reporting is general — no named employer plan or policy document confirms the specific rider structure.
For comparison, since the international picture is often quoted misleadingly: US Medicare remains statutorily barred from covering anti-obesity drugs under a 2003 law. The UK's NICE approved Wegovy in 2023 but caps NHS supply at two years per patient. Saudi Arabia and the UAE cover GLP-1s for obesity under government schemes — an oil-economy outlier, not a template.
IRDAI has shown no signal of mandating GLP-1 coverage within the next eighteen months. The honest forecast is that this stays fully out-of-pocket in India through at least 2027, with the price floor set by generic competition rather than by insurance reform.
Indications — where India leads, matches and lags
India is not uniformly behind on this class. On one indication it is level with the world.
| Indication | India's position | What that means |
|---|---|---|
| MASH / liver fibrosis | Level with the world | CDSCO has approved Wegovy for non-cirrhotic MASH with moderate-to-advanced fibrosis. Given India's NAFLD and MASH burden, this may be the most commercially significant Indian label expansion of 2026. |
| Obesity | On-label | Approved at a BMI of 30 or above, or 27 or above with a weight-related comorbidity — generics included. Indian clinical practice commonly counts PCOS, prediabetes, cardiovascular disease and NAFLD among qualifying comorbidities. |
| Obstructive sleep apnea | Lags | Zepbound holds the US OSA label and is not sold in India. Use here is off-label, justified through Mounjaro's existing diabetes and obesity label. |
| Cardiovascular risk reduction | Partial | Wegovy holds a US cardiovascular indication, and a Mounjaro cardiovascular label is expected globally around mid-2026. The Indian label status for both is unconfirmed. |
Off-label is not the same as unsafe or improper — it is a specific legal and clinical status, and it changes who carries the justification. That is a conversation to have with the prescriber, not a detail to discover afterwards.
What is actually coming
The global pipeline is crowded. The India-specific pipeline is one drug.
Orforglipron (Foundayo) · Eli Lilly
Non-peptide, small-molecule oral GLP-1 receptor agonist
India was a participating site in Lilly’s global Phase 3 obesity trial (ATTAIN-1). Lilly has stated an intent to launch in India, with a regulatory filing expected within months and the second half of 2026 the likeliest approval window. As a small molecule — ordinary chemical synthesis, no cold chain, no injection device — it is exactly the profile that scales in a price-sensitive, cold-chain-limited market.
Not yet confirmed: as of 26 August 2026 there is no confirmed CDSCO filing date, no approval, and no announced India price. “Expected” is a company statement, not a regulatory fact.
Next-generation molecules — no India signal for any of them
| Molecule | Mechanism | Global status | India signal |
|---|---|---|---|
| CagriSemaNovo Nordisk | Cagrilintide plus semaglutide | NDA filed December 2025; an FDA decision is expected around Q4 2026. Underperformed tirzepatide head-to-head in REDEFINE-4. | No India filing, trial-site inclusion or launch signal found. |
| RetatrutideEli Lilly | Triple GLP-1 / GIP / glucagon agonist | Phase 3 topline in July 2026 reported 20.8% weight loss at 80 weeks. Filing targeted for Q1 2027. | None. Indian trial inclusion would be the leading indicator to watch — typically two to four years ahead of a launch. |
| SurvodutideBoehringer Ingelheim / Zealand | Dual GLP-1 / glucagon agonist | Phase 3 ongoing; NDA expected 2026–27. | No India filing, trial-site inclusion or launch signal found. |
CagriSema
Novo Nordisk
- Mechanism
- Cagrilintide plus semaglutide
- Global status
- NDA filed December 2025; an FDA decision is expected around Q4 2026. Underperformed tirzepatide head-to-head in REDEFINE-4.
- India
- No India filing, trial-site inclusion or launch signal found.
Retatrutide
Eli Lilly
- Mechanism
- Triple GLP-1 / GIP / glucagon agonist
- Global status
- Phase 3 topline in July 2026 reported 20.8% weight loss at 80 weeks. Filing targeted for Q1 2027.
- India
- None. Indian trial inclusion would be the leading indicator to watch — typically two to four years ahead of a launch.
Survodutide
Boehringer Ingelheim / Zealand
- Mechanism
- Dual GLP-1 / glucagon agonist
- Global status
- Phase 3 ongoing; NDA expected 2026–27.
- India
- No India filing, trial-site inclusion or launch signal found.
A next-generation drug that is not clearly better than an on-patent competitor is unlikely to be prioritised for an India launch, where the price ceiling is low and generic semaglutide already anchors the market.
There is one more molecule worth naming and dismissing. Oral Wegovy — high-dose oral semaglutide — was approved in the United States in December 2025, and no India launch, filing or timeline signal has been found. The commercial case here is awkward: India's semaglutide patent has already lapsed, and Torrent's Semalix is already a generic oral semaglutide on Indian shelves. India may simply skip it. Indian trade press has separately flagged Chinese oral GLP-1 entrants as a potential disruptor of this same segment.
The patent timeline — India is years ahead on one molecule, not the other
| Molecule | India generic timeline | United States, for comparison |
|---|---|---|
| Semaglutide | Already generic — patent expired 20 March 2026 | Not before roughly December 2031 |
| Tirzepatide | Locked to roughly 2036 — no Indian generic possible before then | Roughly 2036–2039 |
| Next generation (cagrilintide, retatrutide, orforglipron) | 2040s | 2040s |
Practically, India has a two-tier GLP-1 market for the next decade: near-commodity semaglutide and premium-priced tirzepatide, with no legal path to a tirzepatide generic here barring a compulsory licence, for which there is currently no public signal.
What to watch, 2026–2027
- Orforglipron's CDSCO filing or approval. The nearest concrete event on this list, with a second-half-of-2026 window.
- Delhi High Court contempt proceedings over alleged inaction on GLP-1 safety and licensing, with hearings from May 2026. The outcome is unknown as of this writing.
- CGHS eligibility criteria — the first real reimbursement precedent in India, and likely to anchor how private insurers eventually frame coverage. Reported but not confirmed against a government circular.
- Whether the generic price floor keeps falling. This determines whether GLP-1s become genuinely mass-market in India or plateau as an upper-middle-class product.
- Counterfeit enforcement outcomes. A public quality failure in the generic channel would trigger rapid tightening of retail and online distribution.
- Indian trial inclusion for retatrutide or CagriSema — typically the leading indicator of a launch, two to four years ahead of it.
- Advertising enforcement against digital health platforms. The March 2026 advisory explicitly names digital and influencer marketing, and the DCGI audit explicitly included clinics.
Safety, and why a prescriber is mandatory
GLP-1 receptor agonists are Schedule H medicines in India. Prescription-only.
A doctor's evaluation before the first dose exists to screen for contraindications that are real and specific, among them:
- A personal or family history of medullary thyroid carcinoma, or of multiple endocrine neoplasia type 2.
- A history of pancreatitis.
- Severe gastrointestinal disease.
Dose introduction in this class is gradual and physician-supervised — that is how the class is designed to be used, and it is not something to work out from a table. Nothing on this page is a titration plan, and the strengths listed above are price points on a ladder, not instructions.
Beyond the first prescription, supervision is what catches the things that go wrong: side effects that need the dose held rather than pushed, lab values that move in the wrong direction, and the lean-muscle question that determines whether weight lost stays lost. A provider dispensing this class without an evaluation, without baseline labs and without follow-up is not practising safely — and the cold chain matters too. These medicines are stored between 2 and 8°C, and a courier that does not maintain it can deliver a product that is no longer effective.
Talk to a doctor
If you are trying to work out whether any of this applies to you, that is a clinical question and it needs a clinical answer — your history, your labs, and a doctor's individual judgement. An NMC-registered doctor on Kyros can go through it honestly, including the answer that this is not the right treatment for you.
For the shorter version of this story — how the molecule got here and why the Indian timeline looks the way it does — read GLP-1 in India: the cost and history story.
This page is educational reference only. It is not medical advice, not a price quote, and not a recommendation to use any medicine named on it. GLP-1 receptor agonists are prescription-only medicines and must never be taken without an individual doctor's assessment and ongoing supervision. Prices are indicative, move frequently, and vary by manufacturer, city and pharmacy. Brand names appear here to identify products accurately, not as endorsements — Kyros has no commercial relationship with any manufacturer named on this page.